Mitral Valve Repair with a Biodegradable Annuloplasty Ring for Mitral Regurgitation

Pdf
Published: Sep 8, 2023
DOI: https://doi.org/10.12681/jhcvm.33386
Keywords:
Biodegradable ring annuloplasty mitral regurgitation
Yilmaz Zorman
Cardiovascular Surgery, Koç University Hospital, İstanbul, Turkey
Bekir IŞIK
Cardiovascular Surgery, Koç University Hospital, İstanbul, Turkey
Mustafa Serdar YILMAZER
Cardiology Department, Maltepe University Hospital, İstanbul, Turkey
Tamer AKSOY
Anesthesia and Intensive Care Unit Department, Maltepe University Hospital, İstanbul, Turkey
Abstract

Objective: We aimed to evaluate the effectiveness of the mitral valve repair procedure using biodegradable ring implantation to treat severe mitral valve regurgitation.


Method: Between May 2007 and 2009, 23 patients without mitral stenosis underwent mitral valve repair using a biodegradable annuloplasty ring. 3 of the 23 patients are excluded from the study due to discontinuation of follow-up. Preoperative, postoperative 7th day, 3rd month, 6th month, and 1st-year echocardiographic data of 20 patients were collected retrospectively and statistically analyzed with Chi-square and Student T-tests.


Results: At follow-up, transthoracic echocardiography revealed no or trivial regurgitation. Although there was an increase in the mean gradient during the early postoperative period (7th days and 3rd months), there was no statistically significant difference in the mean gradient between the preoperative and late postoperative period (6th month and 1st year). Mean gradients were 3.48±0.64, 2.72±0.31, 2.62±0.25, and 2.58±0.21 mmHg, respectively at 7th days, 3rd months, 6th months, and 1st year. Increased preload due to mitral regurgitation resulted in larger left ventricular end-diastolic volume (LVEDV) and left ventricular end-systolic volume (LVESV) preoperatively of 194.42±21.39 ml (range, 245.00 to 165.00 ml) and 94.23±36.59 ml (range, 203.35 to 52.80 ml) respectively. The decrease in mean LVEDV and LVESV at 1 year was statistically significant, 130.40±11.04 ml (range, 145.00 to 115.00 ml; p<0.001) and 64.21±13.20 ml (range, 80.08 to 40.25 ml; p<0.001), respectively. Additionally, left ventricular ejection fraction (LVEF) reaches the preoperative value (%51.15±14.04) in the 6th month (%51.58±7.32), although there is a decline in the early postoperative period (%47.11±11.22 on 7th day and 46.35±8.03 in 3rd month). One late death occurred. Mitral valve re-operation was necessary for one rheumatic patient.


Conclusion: Annuloplasty using a biodegradable mitral ring has shown desired long-term outcomes with particular advantages compared to traditional annuloplasty rings.

Article Details
  • Section
  • Articles
Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

  This work is licensed under a [Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License|https://creativecommons.org/licenses/by-nc-sa/4.0/]. Authors who publish with this journal agree to the following terms: # Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a CC-BY-NC-SA that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal. # Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g. post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal. # Authors are permitted and encouraged to post their work online (preferably in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See [The Effect of Open Access|http://opcit.eprints.org/oacitation-biblio.html]).

Downloads
Download data is not yet available.
References
Gillinov, A.M., et al., Durability of mitral valve repair for degenerative disease. J Thorac Cardiovasc Surg, 1998. 116(5): p. 734-43.
Mohty, D., et al., Very long-term survival and durability of mitral valve repair for mitral valve prolapse. Circulation, 2001. 104(12 Suppl 1): p. I1-I7.
Flameng, W., P. Herijgers, and K. Bogaerts, Recurrence of mitral valve regurgitation after mitral valve repair in degenerative valve disease. Circulation, 2003. 107(12): p. 1609-13
Flameng, W., et al., Durability of mitral valve repair in Barlow disease versus fibroelastic deficiency. J Thorac Cardiovasc Surg, 2008. 135(2): p. 274-82.
Kalangos, A., et al., Annuloplasty for valve repair with a new biodegradable ring: an experimental study. J Heart Valve Dis, 2006. 15(6): p. 783-90.
Neirotti, R., et al., New technology: valve repair using biodegradable rings. Rev Bras Cir Cardiovasc, 2008. 23(4): p. 556-61.
Cikirikcioglu, M., et al., Pediatric mitral valve repair with the novel annuloplasty ring: Kalangos-Bioring. Asian Cardiovasc Thorac Ann, 2008. 16(6): p. 515-6.
Kalangos, A., et al., Mitral valve repair for rheumatic valve disease in children: midterm results and impact of the use of a biodegradable mitral ring. Ann Thorac Surg, 2008. 86(1): p. 161-8; discussion 168-9.
Carpentier, A., et al., Reconstructive surgery of mitral valve incompetence: ten-year appraisal. J Thorac Cardiovasc Surg, 1980. 79(3): p. 338-48.
Jan T Christenson, Jan,T and Kalangos, A, Use of a Biodegradable Annuloplasty Ring for Mitral Valve Repair in Children February 2009Asian Cardiovascular & Thoracic Annals 17(1):11-2
DOI:10.1177/0218492309102260
Kalangos A, Christenson JT, Beghetti M, Cikirikcioglu M, Kamentsidis D,Aggoun Y. Mitral valve repair for rheumatic valve disease in children: midtermresults and impact of the use of a biodegradable mitral ring.Ann Thorac Surg.2008;86:161-9.
Kalangos A, Sierra J, Vala D, et al: Annuloplasty for valve repair with a new biodegradable ring: an experimental study. J Heart Valve Dis. 2006 Nov;15(6):783-90.
Cikirikcioglu M, Cherian S, Stimec B, et al: Morphologic and angiographic analysis to assess safety of biodegradable mitral annuloplasty ring. J Heart Valve Dis 20:199-204, 2011
Cherian, S, Cikirikcioglu, M, Kalangos, A.,Mitral Annuloplasty Using A Biodegradable Annuloplasty Ring;Operative Techniques in Thoracic and Cardiovascular Surgery
Volume 20, Issue 2, Pages (June 2015)
DOI: /j.optechstcvs. Copyright © 2015 Elsevier Inc. Terms and Conditions
Mrowczynski W, Mrozinski B, Walpoth BH, et al: Does a biodegradable ring enablegrowth of the native tricuspid annulus? STS 46th Annual Meeting and STS/AATS Tech-Con 2010; January 23-27, 2010. Fort Lauderdale, FL, 2010, pp. 48-365
Kalangos A: Mitral valve repair using biodegradable annuloplasty rings.
In: Hetzer R, Rankin JS, Yankah CA (eds). Mitral Valve Repair. Berlin:
Springer Verlag; 2011 (in press).
Wagner DK, Werner PH, Bonchek LI, Shimshak T, Rytel MW.
Successful treatment of post-mitral valve annuloplasty in Aspergillus flavus endocarditis. Am J Med 79:777– 80, 1985.
Vanagt WY, Daenen WJ, Delhaas T.
Propionibacterium acnes endocarditis on an annuloplasty ring in an adolescent boy.
Heart 90:e56, 2004
Pektok E, Sierra J, Cikirikcioglu M, Müller H, Myers PO, Kalangos A.
Midterm results of valve repair with a biodegradable annuloplasty ring for acute endocarditis. Ann Thorac Surg 89:1180-5, 2010
Yakub MA, Sivalingam S, Dillon J, Matsuhama M, Latiff HA, Ramli MF.
Mitral valve repair for congenital mitral valve disease: impact of the use
of a biodegradable annuloplasty ring. Ann Thorac Surg 99:884-90,2015.
Carpentier, A., Cardiac valve surgery--the "French correction". J Thorac Cardiovasc Surg, 1983. 86(3): p. 323-37.
Carpentier, A.F., et al., The "physio-ring": an advanced concept in mitral valve annuloplasty. Ann Thorac Surg, 1995. 60(5): p. 1177-85; discussion 1185-6.
Carpentier, A., et al., A new reconstructive operation for correction of mitral and tricuspid insufficiency. J Thorac Cardiovasc Surg, 1971. 61(1): p. 1-13.